Authors
MJ Sorich, MD Wiese, Andrew Rowland, Ganessan Kichenadasse, RA McKinnon, CS Karapetis
Publication date
2015/1/1
Source
Annals of Oncology
Volume
26
Issue
1
Pages
13-21
Publisher
Elsevier
Description
Background
Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral oncogene (KRAS) exon 2 wild-type tumors. Recent evidence has suggested that other RAS mutations (in exons 3 and 4 of KRAS and exons 2, 3 and 4 of a related gene, NRAS) may also be predictive of resistance.
Methods
Systematic review and meta-analysis of randomized, controlled trials (RCTs) evaluating anti-EGFR mAbs that have assessed tumors for new RAS mutations. Tumors with the new RAS mutations were compared with both tumors without any RAS mutations and tumors with KRAS exon 2 mutations with respect to anti-EGFR treatment progression-free survival (PFS) and overall survival (OS) benefit.
Results
Nine RCTs comprising a total of 5948 participants evaluated for both KRAS exon 2 and new RAS mutations met the …
Scholar articles
MJ Sorich, MD Wiese, A Rowland, G Kichenadasse… - Annals of Oncology, 2015